Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.

Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.

Abstract: The present invention provides a high throughput method to quantify and characterize the size and integrity of viruses and viral molecules. In one embodiment, the present invention provides a method to quantify and characterize size and integrity of Foot and Mouth Disease virus (FMDV) using chromatographic system and in-line Dynamic Light Scattering (DLS) technique. In one embodiment, the present invention further comprises a column-switching system for running multiple analyses simultaneously. The present invention also provides a method to develop and evaluate FMDV containing products for preventing Foot and Mouth Disease (FMD). In one embodiment, the methods described herein assess the stability of FMDV. In another embodiment, the methods described herein serve as in-process quality control for a manufacturing process of FMD vaccine.

Abstract: The present invention relates to a pharmaceutical combination for inducing one or more immune responses and/or for enhancing effectiveness of vaccination in the host, which is capable of inducing cross-protection against multiples strains and/or serotypes of a virus. In one embodiment, the pharmaceutical combination is able to generate protection in food producing animals, such as cattle, sheep, goats, swine and other cloven-hoofed animals with fewer vaccination campaigns.

Abstract: The present invention provides a high throughput method to quantify and characterize the size and integrity of viruses and viral molecules. In one embodiment, the present invention provides a method to quantify and characterize size and integrity of Foot and Mouth Disease virus (FMDV) using chromatographic system and in-line Dynamic Light Scattering (DLS) technique. In one embodiment, the present invention further comprises a column-switching system for running multiple analyses simultaneously. The present invention also provides a method to develop and evaluate FMDV containing products for preventing Foot and Mouth Disease (FMD). In one embodiment, the methods described herein assess the stability of FMDV. In another embodiment, the methods described herein serve as in-process quality control for a manufacturing process of FMD vaccine.

Abstract: The present invention provides a high throughput method to quantify and characterize the size and integrity of viruses and viral molecules using chromatographic system and in-line Dynamic Light Scattering (DLS) technique. In one embodiment, the present method quantifies and characterizes the size and integrity of enveloped or non-enveloped virus, live or live-attenuated or inactivated virus, recombinant viral vectors, or virus-like particles (VLPs). In one embodiment, the present invention comprises a column-switching system for running multiple analyzes simultaneously. The present invention also provides a method to develop and evaluate virus containing products for the prevention of viral diseases. In another embodiment, the methods described herein serve as in-process quality control for manufacturing processes of virus vaccines.

Abstract: The present invention provides a high throughput method to quantify and characterize the size and integrity of viruses and viral molecules using chromatographic system and in-line Dynamic Light Scattering (DLS) technique. In one embodiment, the present method quantifies and characterizes the size and integrity of enveloped or non-enveloped virus, live or live-attenuated or inactivated virus, recombinant viral vectors, or virus-like particles (VLPs). In one embodiment, the present invention comprises a column-switching system for running multiple analyses simultaneously. The present invention also provides a method to develop and evaluate virus containing products for the prevention of viral diseases. In another embodiment, the methods described herein serve as in-process quality control for manufacturing processes of virus vaccines.

Abstract: The present invention provides a high throughput method to quantify and characterize the size and integrity of viruses and viral molecules. In one embodiment, the present invention provides a method to quantify and characterize size and integrity of Foot and Mouth Disease virus (FMDV) using chromatographic system and in-line Dynamic Light Scattering (DLS) technique. In one embodiment, the present invention further comprises a column-switching system for running multiple analyses simultaneously. The present invention also provides a method to develop and evaluate FMDV containing products for preventing Foot and Mouth Disease (FMD). In one embodiment, the methods described herein assess the stability of FMDV. In another embodiment, the methods described herein serve as in-process quality control for a manufacturing process of FMD vaccine.

Abstract: The invention concerns a biological organism comprising at least: (i) a nucleic acid coding for all or part of an antibody, said antibody being expressed at the surface of a host cell and capable of being fixed to a polypeptide present at the surface of a cytotoxic effector cell or of a T-helper lymphocyte and involved in the process of activating such a cell and (ii) a nucleic acid coding for all or part of a polypeptide involved in the stimulation of an immune response or in attraction to the site of expression and activation of cytotoxic effector cells or of T-helper lymphocytes, said polypeptide being selected among chemokines and co-stimulation molecules. The invention also concerns a host cell and a pharmaceutical composition containing said biological organism and their therapeutic or prophylactic uses.

Abstract: A device and method for delivery of EPO to a patient using an implanted device that continuously releases EPO.